Article ID Journal Published Year Pages File Type
5123754 Obesity Medicine 2017 7 Pages PDF
Abstract

•Plasma adiponectin levels are significantly higher in subjects treated with OBERAY than with placebo.•OBERAY for overweight and obese subjects resulted in statistically significant reductions in BMI, WC, body fat, visceral fat, VAI, TC and lipid profiles from the baseline.•OBERAY is shown significant difference in the reduction of important components of skin fold thickness, subcutaneous and skeletal muscle fat compared to placebo.

PurposeTo determine the effect of OBERAY capsules on serum lipid profiles, plasma adiponectin levels, body fat, skin fold thickness and an anthropometric measurements in overweight and obese individuals.MethodsIn this randomized, double-blind, placebo-controlled study, 72 overweight and obese participants were randomly assigned to receive either 1000 mg of OBERAY or a placebo, daily for 180 days. At baseline, after 90 days and 180 days of treatment, anthropometric parameters, total cholesterol, high density lipoprotein, low density lipoprotein, very low density lipoprotein, triglycerides, plasma adiponectin, body fat and skin fold variables were measured.Results180 days of OBERAY treatment resulted in a significant increase in mean high density lipoprotein and decrease in other lipid profiles, plasma adiponectin, BMI, Waist Circumference, total body fat, skin fold parameters, subcutaneous and skeletal muscle fat.ConclusionOur findings suggests that, OBERAY is an effective treatment of weight control in overweight and obese Indian population.

Related Topics
Health Sciences Medicine and Dentistry Endocrinology, Diabetes and Metabolism
Authors
, , , ,